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a b s t r a c t
Background: Although recent studies have shown an association between obesity and adverse coronavirus
disease 2019 (COVID-19) patient outcomes, there is a paucity in large studies focusing on hospitalized
patients. We aimed to analyze outcomes associated with obesity in a large cohort of hospitalized COVID19 patients.
Methods: We performed a retrospective study at a tertiary care health system of adult patients with
COVID-19 who were admitted between March 1 and April 30, 2020. Patients were stratiﬁed by body
mass index (BMI) into obese (BMI ≥ 30 kg/m 2) and non-obese (BMI < 30 kg/m 2) cohorts. Primary
outcomes were mortality, intensive care unit (ICU) admission, intubation, and 30-day readmission.
Results: A total of 1983 patients were included of whom 1031 (51.9%) had obesity and 952 (48.9%) did
not have obesity. Patients with obesity were younger (P < 0.001), more likely to be female (P < 0.001)
and African American (P < 0.001) compared to patients without obesity. Multivariable logistic models
adjusting for differences in age, sex, race, medical comorbidities, and treatment modalities revealed no
difference in 60-day mortality and 30-day readmission between obese and non-obese groups. In these
models, patients with obesity had increased odds of ICU admission (adjusted OR, 1.37; 95% CI, 1.07−1.76;
P = 0.012) and intubation (adjusted OR, 1.37; 95% CI, 1.04−1.80; P = 0.026).
Conclusions: Obesity in patients with COVID-19 is independently associated with increased risk for ICU
admission and intubation. Recognizing that obesity impacts morbidity in this manner is crucial for
appropriate management of COVID-19 patients.
© 2021 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights
reserved.

Introduction
The outbreak of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was ﬁrst reported in Wuhan, China in December
2019 and has since led to the global coronavirus disease 2019
(COVID-19) pandemic, which has resulted in over 108 million
cases and 2,300,000 deaths worldwide as of February 2021 [1].
As this disease has become more prevalent, public health interest has increased regarding vulnerable patient populations. Current
guidelines from the Centers for Disease Control and Prevention suggest that individuals with cancer, chronic kidney disease, chronic

∗ Corresponding author.
E-mail address: ssuresh1@hfhs.org (S. Suresh).

obstructive pulmonary disease, history of solid organ transplant,
cardiac conditions, sickle cell disease, type 2 diabetes, and obesity
may be at increased risk for severe illness from COVID-19 [2].
Obesity has been studied extensively, as it is a modiﬁable risk
factor with a high worldwide prevalence. An early study in China
found that among 383 hospitalized patients with COVID-19, having
overweight or obesity was associated with substantially increased
risk for developing severe pneumonia [3]. A more recent retrospective study that evaluated factors associated with hospitalization
at a large academic health system in New York City showed that
obesity and age were the most important predictors for admission
[4]. Although there has been a fair amount of recently published
research studying the association between obesity and COVID-19,
most of these studies have been relatively small in scale, and only a
few have focused speciﬁcally on hospital-based outcomes. Because

https://doi.org/10.1016/j.orcp.2021.02.006
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Michigan ranks ﬁfth for obesity within the United States and was
an epicenter of the COVID-19 pandemic during the initial infectious peak, our patient population provided a representative model
to assess how COVID-19 is affecting individuals with obesity. We
conducted this study to better understand the demographic characteristics of patients with obesity who were hospitalized with
COVID-19 within our large metropolitan health system and to evaluate the link between obesity and adverse clinical outcomes in this
population.

Materials and methods
Study design
This study was approved by the Henry Ford Health System Institutional Review Board. The study was a retrospective
medical record review at a large tertiary care health system in
Detroit, Michigan. Patients with SARS-CoV-2 infection conﬁrmed
by positive polymerase chain reaction testing of a nasopharyngeal
specimen were included. The study cohort consisted of patients
who were admitted and discharged to any of the 5 hospitals within
the Henry Ford Health System between March 1 and April 30, 2020.
Patients who were discharged directly from the emergency room
or evaluated in outpatient clinics were not included in this study.
If patients were admitted multiple times during the study interval,
only the index admission following a positive COVID-19 test result
was considered.

Data collection
A team of physicians performed a manual retrospective chart
review on a standardized data collection form using the electronic
medical record. Demographic data were collected from the electronic medical record including patient sex, age, race, body mass
index (BMI), and current or prior cigarette use. Patients with obesity
were stratiﬁed by obesity class based on BMI with class 1 obesity
deﬁned as BMI 30.0–34.9 kg/m2 , class 2 obesity deﬁned as BMI
35.0–39.9 kg/m2 , and class 3 obesity deﬁned as BMI equal to or
greater than 40.0 kg/m2 . Primary outcomes included 60-day mortality, length of hospitalization, intensive care unit (ICU) admission,
length of ICU admission, intubation, discharge home vs. hospice,
and 30-day readmission. Mortality was calculated based on death
of any cause either during the hospitalization or within 60 days of
the patient’s index admission.
In addition, the presence of baseline medical comorbidities
including diabetes, sleep apnea, chronic obstructive pulmonary
disease, asthma, hypertension, cardiovascular disease, and malignancy were recorded. Cardiovascular disease was deﬁned by the
presence of coronary artery disease, prior myocardial infarction,
cerebrovascular disease, congestive heart failure, cardiac arrhythmia, or congenital heart disease.
Finally, data was collected on the use of various medical
treatment modalities for COVID-19 including Hydroxychloroquine,
Remdesivir, Tocilizumab, and plasmapheresis. During the study
period, administration of Hydroxychloroquine 400 mg twice daily
for 1 day followed by 200 mg twice daily for 4 days to complete
a 5-day treatment course was considered standard of care at our
institution for patients with an acute COVID-19 infection. A longer
treatment duration was sometimes used in select patients based
on the severity of their disease course. The other treatment modalities were considered experimental at the time of the study and
therefore did not have a strict administration protocol in place.
Tocilizumab and plasmapheresis were typically reserved for critically ill patients requiring ICU admission.
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Statistical analysis
All continuous data were reported as mean ± standard deviation, while categorical data were reported as counts and column
percentages. For continuous variables, univariate two-group comparisons were performed using independent 2-sample t-tests if
the variable was normally distributed and Wilcoxon rank sum
tests if the variable was not normally distributed. For categorical variables, univariate two-group comparisons were performed
using chi-square tests when expected cell counts were > 5 and
Fisher’s exact tests when expected cell counts were < 5. Relative risk for the outcomes of interest were assessed using the
log-binomial method. Multivariable logistic regressions were performed to examine the effect of obesity on the outcomes while
adjusting for differences in patient demographics, medical comorbidities, and treatment modalities. Statistical signiﬁcance was set
at P < 0.05. All analyses were performed using SAS 9.4 (SAS Institute
Inc., Cary, NC).

Results
A total of 1983 patients who tested positive for COVID-19 were
hospitalized between March 1 and April 30, 2020 (993 [50.1%] men
and 990 [49.9%] women), with a mean age of 63.8 ± 16.5 years.
Of these patients, 1031 (51.9%) had obesity and 952 (48.9%) did
not have obesity. The mean BMI for patients with obesity was
37.8 ± 7.5 and 24.9 ± 3.4 for patients without obesity. Among
patients with obesity, 463 (45%) had class I obesity, 290 (28%)
had class II obesity, and 278 (27%) had class III obesity. Table 1
shows baseline characteristics for patients with and without obesity.
Patients with obesity were younger (58.2 years vs. 69.9 years;
P < 0.001), more likely to be female (55% women vs. 45% men;
P < 0.001), and a higher proportion were African American
(63% vs. 49%; P < 0.001) compared to those in the non-obese
group. Patients with obesity were also more likely to be diabetic (41% vs. 35%; P = 0.010) and have obstructive sleep apnea
(15% vs. 5%; P < 0.001), but were less likely to have cardiovascular disease (25% vs. 33%; P < 0.01) and malignancy (5% vs. 10%;
P < 0.01).
Patients with obesity were more likely than non-obese individuals to receive treatment with Hydroxychloroquine (84%
vs. 76%; P < 0.001) and Tocilizumab (6% vs. 3%; P < 0.001).
There was no difference in the proportion of patients who
received Remdesivir and Plasmapheresis treatment in each
group.
Patients with obesity had a signiﬁcantly lower 60-day mortality
compared to patients without obesity (15% vs. 25%; P < 0.001). A
total of 156 (15%) patients with obesity died and 1 patient in this
group was discharged to hospice, while 242 (25%) patients without obesity died and 7 (1%) were discharged to hospice during the
study period (P < 0.001). There was no signiﬁcant difference for
ICU admission (24% vs. 21%; P = 0.078), need for intubation (18%
vs. 15%; P = 0.157), or 30-day readmission (9% vs. 11%; P = 0.319)
in patients with and without obesity. Also, there was no signiﬁcant difference in length of hospital stay (7.41 days vs. 7.44 days;
P = 0.913) or length of ICU stay (8.87 days vs. 8.19 days; P = 0.289)
between these two groups (Table 2).
When stratiﬁed by obesity class, the relative risk for 60-day mortality was signiﬁcantly lower in the cohort of patients with obesity
compared to the cohort of patients without obesity across all obesity classes (Table 3). There was a signiﬁcant increased risk for ICU
admission (relative risk 1.33; 95% CI 1.06−1.67) and intubation (relative risk 1.43; 95% CI 1.09−1.86) in patients with class III obesity
compared to patients without obesity.
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Table 1
Baseline patient characteristics.
Patient Characteristics
(N = 1983)

Total
(n = 1983)

Obese (n = 1031)

Non-Obese (n = 952)

P-valuea

Age (years), mean ± SD
Sex, N (%)
Female
Male
Race, N (%)
African American
White
Asian
Hispanic
Other
Unknown
BMI (kg/m2 ), mean ± SD
Obesity class, N (%)
Non-obese (< 30)
Class 1 (30−34.9)
Class 2 (35−39.9)
Class 3 (>40)
Medical comorbidities, N (%)
Diabetes
Sleep apnea
COPD/Asthma
Hypertension
Cardiovascular disease
Malignancy
Treatments, N (%)
Hydroxychloroquine
Remdesivir
Tocilizumab
Plasmapheresis

63.82 ± 16.55

58.20 ± 15.30

69.91 ± 15.68

< 0.001
< 0.001

990 (50%)
993 (50%)

566 (55%)
465 (45%)

424 (45%)
528 (55%)

1115 (56%)
640 (32%)
39 (2%)
7 (0%)
92 (5%)
90 (5%)

647 (63%)
283 (27%)
11 (1%)
5 (1%)
41 (4%)
44 (4%)
37.75 ± 7.48

468 (49%)
357 (38%)
28 (3%)
2 (0%)
51 (5%)
46 (5%)
24.87 ± 3.41

952 (48%)
463 (23%)
290 (15%)
278 (14%)

N/A
463 (45%)
290 (28%)
278 (27%)

952 (100%)
N/A
N/A
N/A

N/A

760 (38%)
196 (10%)
383 (19%)
1345 (68%)
572 (29%)
142 (7%)

423 (41%)
151 (15%)
213 (21%)
697 (68%)
261 (25%)
50 (5%)

337 (35%)
45 (5%)
170 (18%)
648 (68%)
311 (33%)
92 (10%)

0.010
< 0.001
0.114
0.825
< 0.001
< 0.001

1586 (80%)
17 (1%)
84 (4%)
5 (0%)

862 (84%)
10 (1%)
60 (6%)
2 (0%)

724 (76%)
7 (1%)
24 (3%)
3 (0%)

< 0.001
0.569
< 0.001
0.676

< 0.001

< 0.001

BMI, body mass index; COPD, chronic obstructive pulmonary disease; N/A, not applicable; SD, standard deviation.
a
P-values reported using 2-sample t-test for age, Wilcoxon rank sum test for BMI, and chi-square or Fisher’s exact test for other patient characteristics.
Table 2
Primary and secondary outcomes in obese and non-obese patients.
Patient Outcomes

Total
(n = 1983)

Obese (n = 1031)

Not Obese (n = 952)

P-valuea

60-day mortality, N (%)
ICU admission, N (%)
Intubation, N (%)
30-day readmission, N (%)
Length of hospital stay (days), mean ± SD
Length of ICU stay (days), mean ± SD

398 (20%)
448 (23%)
330 (17%)
156 (8%)
7.42 ± 6.28
8.54 ± 6.76

156 (15%)
249 (24%)
183 (18%)
80 (9%)
7.41 ± 6.36
8.87 ± 6.61

242 (25%)
199 (21%)
147 (15%)
76 (11%)
7.44 ± 6.19
8.19 ± 6.91

< 0.001
0.078
0.157
0.319
0.913
0.289

ICU, intensive care unit; SD, standard deviation.
a
P values reported using Chi-square test and 2-sample t-test (length of hospital stay and length of ICU stay).
Table 3
Risk of morbidity and mortality in obese patients compared to non-obese patients
stratiﬁed by obesity class.

Table 4
Multivariable logistic regression showing effect of obesity on morbidity and
mortality.

Relative Risk (95% CI)
Outcome
60-day mortality
ICU admission
Intubation
30-day readmission

Class I Obesity
0.65 (0.51−0.82)
1.05 (0.85−1.30)
0.97 (0.75−1.26)
1.04 (0.73−1.48)

Class II Obesity
0.58 (0.43−0.78)
1.17 (0.92−1.48)
1.18 (0.89−1.57)
0.72 (0.45−1.17)

Class III Obesity
0.53 (0.38−0.72)
1.33 (1.06−1.67)
1.43 (1.09−1.86)
0.71 (0.43−1.16)

CI, conﬁdence interval; ICU, intensive care unit.

Multivariable logistic regression models were performed to
examine the effect of obesity on the odds of death, ICU admission, intubation, and 30-day readmission, while adjusting for other
variables. When adjusted for differences in age, sex, race, medical
comorbidities, and treatment modalities, obesity was not independently associated with 60-day mortality (adjusted odds ratio [OR]
1.10; 95% CI, 0.83−1.44; P = 0.512). The multivariable adjusted
model showed that patients with obesity were at increased risk
for ICU admission (adjusted OR, 1.37; 95% CI, 1.07−1.76; P = 0.012)
and intubation (adjusted OR, 1.37; 95% CI, 1.04−1.80; P = 0.026), but
not for 30-day readmission (adjusted OR 0.91; 95% CI, 0.62−1.35; P

Outcome

Odds Ratio

95% CI

P-valuea

60-day mortality
ICU admission
Intubation
30-day readmission

1.10
1.37
1.37
0.91

0.83−1.44
1.07−1.76
1.04−1.80
0.62−1.35

0.512
0.012
0.026
0.647

ICU, intensive care unit.
a
P values reported using a multivariable logistic regression model adjusting
for differences in age, sex, race, medical comorbidities, and treatments received
between the obese and non-obese groups.

= 0.647) (Table 4). A secondary analysis was performed stratifying
our cohort into males and females with obesity, again adjusting for
other differences between these two groups (Table 5). This model
showed that male patients with obesity did not have increased
risk for any of the measured outcomes whereas females were
at increased risk for ICU admission (adjusted OR, 1.53; 95% CI,
1.06–2.22; P = 0.025) and intubation (adjusted OR, 1.59; 95% CI,
1.04–2.44; P = 0.034) but not 60-day mortality or 30-day readmission.
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Table 5
Multivariable logistic regression stratiﬁed by sex showing effect of obesity on morbidity and mortality.
Males

Females

Outcome

OR (95% CI)

P-valuea

OR (95% CI)

P-valuea

60-day mortality
ICU admission
Intubation
30-day readmission

1.18 (0.81, 1.73)
1.28 (0.91, 1.79)
1.25 (0.86, 1.80)
0.98 (0.57, 1.69)

0.3834
0.1547
0.2420
0.9382

1.05 (0.70, 1.58)
1.53 (1.06, 2.22)
1.59 (1.04, 2.44)
0.86 (0.49, 1.49)

0.8181
0.0247
0.0344
0.5180

OR, odds ratio; CI, conﬁdence interval; ICU, intensive care unit.
a
P values reported using a multivariable logistic regression model adjusting for
differences in age, race, medical comorbidities, and treatments received between
the obese and non-obese groups.

Discussion
In this study, we identiﬁed obesity to be an independent risk factor for ICU admission and intubation among patients hospitalized
with COVID-19 but not associated with 60-day mortality or 30-day
readmission rate. Interestingly, the link between obesity and illness severity was primarily observed in female patients but not in
their male counterparts. Our study is amongst the largest to date
evaluating the association between obesity and COVID-19 related
morbidity and mortality within a single hospital system.
Our study cohort included patients who were hospitalized across multiple medical facilities within the larger Detroit
metropolitan area, a region which has been heavily impacted by
the COVID-19 pandemic. Almost 52% of patients in our study had
obesity which is signiﬁcantly higher than the prevalence of obesity within the Detroit metropolitan area (34.6%) based on data
from 2014 [5]. Our patient population was notably unique compared to other studies in that it included a signiﬁcant proportion
of African Americans, who in prior studies have been shown to
be disproportionately affected by COVID-19 [6–8]. While African
Americans make up 14% of the population in the state of Michigan, there is a much higher population within the city of Detroit,
where 79% of individuals are African American [9]. In our study,
African Americans made up 56% of the study population and were
also signiﬁcantly more likely to have obesity compared to any other
demographic group. Patients with obesity who were hospitalized
with COVID-19 were also younger than their non-obese counterparts. This suggests that obesity may augment disease severity and
potentially predispose younger individuals with obesity to require
hospitalization. Our results corroborate ﬁndings from Kass et al.,
which showed an inverse correlation between age and BMI in a
population of 265 patients hospitalized with COVID-19 [10].
Comparing mortality rate between the two groups, obesity
was surprisingly associated with a signiﬁcant decrease in 60-day
mortality, and when patients were stratiﬁed by obesity class, the
relative risk for death was signiﬁcantly lower in the cohort of
patients with obesity compared to the non-obese cohort across all
obesity classes. This association was not seen with regard to length
of hospitalization, ICU admission rate, length of ICU stay, need for
intubation, and 30-day readmission rate, which were similar in
both groups. To account for confounding variables, a multivariable logistic regression model was used to adjust for differences
in patient age, sex, race, medical comorbidities, and treatment
modalities between obese and non-obese groups. This multivariate analysis showed that obesity was not independently associated
with decreased mortality; however, obesity was found to be a risk
factor for ICU admission and intubation in hospitalized patients. To
further examine this relationship, we stratiﬁed our cohort into male
and female patients and the same outcomes were again assessed.
Surprisingly, the association between obesity and increased illness
severity (i.e., patients requiring ICU admission or intubation) and

was only signiﬁcant in the female population while male patients
with obesity were not at increased risk for morbidity or mortality.
These conclusions highlight some interesting discussion points.
Several smaller retrospective studies have reported similar results
linking obesity to increased COVID-19 illness severity [11–13]. The
etiologies for this are likely multifactorial, ranging from decreased
cardiorespiratory reserve and thrombogenesis to hyperimmunereactivity [14]. Some studies have suggested that the expression
of angiotensin-converting enzyme 2, the functional receptor of
SARS-CoV-2, is upregulated in adipocytes of patients with obesity, which turns adipose tissue into a potential viral reservoir [15],
while others have implicated various cytokine pathways that may
be ampliﬁed in these individuals [16]. Regardless of the underlying
mechanism, there is strong evidence that individuals with obesity may be more likely to develop severe illness due to COVID-19.
The predilection for female patients with obesity for having worse
outcomes than males however has not been previously established. Most studies to date reporting COVID-19 outcomes in the
general population, including one large meta-analysis looking at
over 21,000 patients [17], have found that males tend to have a
more severe disease and higher mortality compared to females.
In comparison, literature on gender-based outcomes in patients
with obesity is limited. One study which tracked 215 hospitalized
COVID-19 patients with obesity found that mortality was signiﬁcantly higher males [18], whereas a more recent study using data
from a UK Biobank found that a higher BMI was associated with
a stronger risk of COVID-19 mortality in women than men [19].
The ﬁndings from our study suggest that perhaps other factors
including waist-to-hip ratio and distribution of adiposity may play
a role in explaining the differences in outcomes between males and
females.
Another question that arises then is why an association was
not seen between obesity and mortality in our study. While some
published studies have shown that there is a correlation between
obesity and increased mortality in COVID-19 patients [18,20–22],
most of these results have been based on smaller sample sizes and
often were not adjusted for potential confounding variables. Our
study suggests that although obesity may predispose individuals to
more severe illness, overall mortality is unaffected when adjusted
for patient age and other medical risk factors including diabetes
and cardiovascular disease. Perhaps patients with obesity who are
otherwise metabolically healthy are more likely to recover from
a severe disease course, while those with other underlying risk
factors are less likely to mount the same robust recovery.
Our study has a few notable limitations. Primarily, it may not
be generalizable since our data were collected from a single large
health system, and the demographics of the patient cohort may
not be reﬂective of the general population. Likewise, the resources
and workforce available at a tertiary care facility such as ours are
not readily available elsewhere, and this may have affected patient
outcomes. In addition, we only focused on evaluating patients who
required hospital admission and did not capture the large proportion of patients who were managed in the outpatient setting
or were discharged home from the emergency department. Other
measurements of obesity such has waist circumference or waist-tohip ratio would have been ideal to include in our analysis however
these variables were unfortunately unable to be collected via retrospective chart review. Finally, as with any retrospective study,
results may be subject to confounding bias from other unknown
variables.
In conclusion, our study found that patients with obesity who
were hospitalized with COVID-19, were younger, more likely to be
female, and were more represented by African Americans. These
patients were also more likely to have medical comorbidities such
as diabetes and obstructive sleep apnea while less likely to have
cardiovascular disease and malignancy. When adjusted for other
175
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potential confounding variables, obesity was independently associated with increased rate of ICU admission and intubation primarily
in female patients. However, there was no association between
obesity and overall mortality or hospital readmission rate in these
otherwise healthy patients, suggesting that despite the more severe
disease course, they are likely to recover compared to their counterparts with other risk factors. As healthcare providers continue
to care for a diverse patient population during this pandemic, it is
important to recognize that obesity can independently inﬂuence
disease severity as this may help inform medical decisions about
triaging, allocation of resources, and appropriate escalation of
care.
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